Shots:
Enodia Therapeutics has entered into a research collaboration & license agreement with Pfizer to discover & develop Sec61-targeting small-molecule therapeutics leveraging Enodia’s platform
As per the deal, Enodia will screen, optimize, & develop Sec61 inhibitor candidates against multiple collaboration targets, while Pfizer will assume responsibility for clinical development, manufacturing, regulatory affairs, & commercialization after…
